Safety and immunogenicity of influenza vaccination in individuals infected with HIV
- PMID: 12477415
- DOI: 10.1016/s0264-410x(02)00511-x
Safety and immunogenicity of influenza vaccination in individuals infected with HIV
Abstract
Influenza can cause severe complications in HIV infected individuals leading to increases in hospitalisation and mortality. Vaccination is recommended for such individuals, but some studies reported that immunisation against influenza may stimulate an increase of HIV viral load and decrease of CD4+ cells count. A review of published studies, including our study carried out in HIV former drug addicts, indicates that vaccination against influenza is well tolerated in both children and adult individuals with HIV, but response to vaccination is lower than that observed in immunocompetent individuals. Most studies, including our own, show that vaccination does not induce significant changes in viral load and CD4+ cell counts. In studies reporting modifications of such parameters there is a general agreement that the increased viral replication is usually transient and unable to determine a clear, measurable progression of the underlying HIV disease. Therefore, vaccination against influenza can be safely administered to HIV infected people.
Similar articles
-
Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy.Mem Inst Oswaldo Cruz. 2007 Jun;102(4):501-8. doi: 10.1590/s0074-02762007005000055. Mem Inst Oswaldo Cruz. 2007. PMID: 17612772
-
Comparison of the effects of acute influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts.J Clin Virol. 2003 Apr;26(3):307-15. doi: 10.1016/s1386-6532(02)00047-1. J Clin Virol. 2003. PMID: 12637080 Review.
-
[Risks and benefits of influenza and pneumococcal immunization in HIV-1 infected individuals].Ann Ig. 2003 Sep-Oct;15(5):567-73. Ann Ig. 2003. PMID: 14969311 Review. Italian.
-
Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.J Infect Dis. 2000 Feb;181(2):725-8. doi: 10.1086/315246. J Infect Dis. 2000. PMID: 10669363 Clinical Trial.
-
Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy.J Med Virol. 2006 Apr;78(4):440-5. doi: 10.1002/jmv.20559. J Med Virol. 2006. PMID: 16482542 Clinical Trial.
Cited by
-
Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis.BMC Infect Dis. 2006 Sep 11;6:138. doi: 10.1186/1471-2334-6-138. BMC Infect Dis. 2006. PMID: 16965629 Free PMC article.
-
High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.J Clin Immunol. 2014 Aug;34(6):655-62. doi: 10.1007/s10875-014-0054-z. Epub 2014 May 14. J Clin Immunol. 2014. PMID: 24824648 Clinical Trial.
-
Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals.BMC Immunol. 2012 Aug 31;13:49. doi: 10.1186/1471-2172-13-49. BMC Immunol. 2012. PMID: 22937824 Free PMC article.
-
Influenza vaccination in HIV-positive subjects: latest evidence and future perspective.J Prev Med Hyg. 2013 Mar;54(1):1-10. J Prev Med Hyg. 2013. PMID: 24396998 Free PMC article. Review.
-
Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore.Hum Vaccin Immunother. 2017 Mar 4;13(3):551-560. doi: 10.1080/21645515.2016.1246636. Epub 2017 Feb 17. Hum Vaccin Immunother. 2017. PMID: 28277090 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials